MA-908-DEVICES
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the latest in international adoption of the MX908 for trace detection and identification of priority drugs and chemical threats. DrugDetect EU and NATO Support and Procurement Agency (NSPA) have both entered into new contracts to deploy the MX908, a handheld high-pressure mass spectrometry (HPMS) device. The MX908 will be used in a variety of settings, from military applications to correctional facilities.
The DrugDetect EU project aims to quickly and effectively detect a large range of drugs in correctional institutions and prisons in several European countries to prevent drugs from entering and circulating in facilities. A contract was awarded to 908 Devices and the first two units shipped in recent months to Belgium and Greece, with more units expected to be procured. Operational validation demonstrated the effectiveness of the MX908 in detecting and identifying trace amounts of drug samples, including cocaine, heroin, methamphetamine and others. 908 Devices is also conducting target development work for an additional 15 targets identified by the DrugDetect EU project.
"The MX908 is an incredibly flexible device that quickly and effectively identifies drugs and enables us to analyze results quickly across our 34 prisons,” said Paul Van Tigchelt, Minister of Justice, Belgium. “We’re committed to combatting drug use in our prisons, and simultaneously protecting our staff, and the MX908 empowers our decision-making with peace of mind.”
In addition to the DrugDetect EU project, the NSPA contract is significant as it streamlines the procurement process of the MX908 device for all 32 NATO member states and four additional countries. Specifically, the agreement is valid for up to five years and includes the ability to purchase up to approximately 80 units, of which orders have already been fulfilled and more expected. NATO countries and their allies can use the MX908 at the point of need in a variety of environmental conditions and analyze trace level samples in any state, including solid, liquid, gas/vapor and aerosol. The device is frequently used for military CBRNE applications.
“We’re honored to partner with the NATO Support and Procurement Agency and DrugDetect EU project as they work to advance detection and identification of chemical threats across Europe,” said Kevin J. Knopp, CEO and co-founder of 908 Devices. “The versatility of our technology empowers users with life-saving insights and our customers are utilizing the MX908 on the frontlines to stem the flow of drugs and other illicit substances to mitigate damage throughout the region.”
The MX908 is a multi-mission handheld mass spectrometer utilized by elite responders conducting chemical, explosive, priority drug and HazMat operations around the world. Powered by HPMS and featuring an evolving target list, the MX908 identifies compounds at trace levels with a high level of sensitivity and unparalleled selectivity to deliver quick, actionable insights to its users.
To learn more about 908 Devices, please visit: 908devices.com.
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.
About NSPA
The NATO Support and Procurement Agency (NSPA) is NATO’s lead organization for multinational acquisition, support and sustainment in all domains. NSPA is headquartered in the Grand Duchy of Luxembourg, with main operational centres in France, Hungary and Italy. The Agency employs over 1,500 staff and oversees more than 500 contractors worldwide.
About DrugDetect EU
The DrugDetect project aims to procure an innovative solution for the automatic detection of a large range of drugs in correctional institutions and prisons, that is available 24/7, does not cause delays in internal processes, does not require minimal human intervention, and is GDPR compliant. The DrugDetect project receives co-funding by the COSME program of the European Union under grant agreement No 101036225. The project’s partners include the Center for Security Studies (KEMEA), the Custodial Institutions Agency (DJI), the Directorate General of Penitentiary Institutions (DG-EPI), and the Spanish Ministry of the Interior (ESMIR).
Forward Looking Statements for 908 Devices
This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312190110/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MBK Partners: Welcoming the Court’s Decision to Prohibit Cumulative Voting for Director Appointments21.1.2025 12:31:00 CET | Press release
Korea Zinc’s Extraordinary General Meeting to Be Conducted Fairly Using a Simple Voting Method MBK Partners and Young Poong, the largest shareholders of Korea Zinc, issue the following statement regarding today’s decision by the Seoul Central District Court’s Civil Division 50 to grant an injunction prohibiting the use of cumulative voting for director appointments at Korea Zinc: MBK Partners and Young Poong welcome the court’s decision to prohibit cumulative voting and view this outcome as a natural and lawful conclusion. The cumulative voting request filed by Yumi Development, for the sole purpose of securing Chairman Yoon Bum Choi’s position, failed to meet the procedural requirements outlined in Article 382-2 of the Korean Commercial Act. The court ruled that while Yumi Development submitted the cumulative voting request on December 10, Korea Zinc’s Articles of Incorporation at that time explicitly stated, “the cumulative voting system shall not apply.” As such, the request violate
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer21.1.2025 12:30:00 CET | Press release
Newly created role of Chief Patient Officer reinforces Compass’ vision of working to achieve broad and equitable access to COMP360, if approved Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by the company are focused on addressing unmet needs in current clinical care and are designed to improve patient outcomes. “Steve has spent the past four years working to deeply understand barriers to care for patients living with serious mental health conditions and he is committed to helping find solutions to address those barriers,” said Kabir Nath, CEO of Compass Pathways. “Steve shares
Epsilon Carbon Launches Terrablack, a High-Performing and Environment Friendly Recovered Carbon Black for the Tire and Non-Tire Industries21.1.2025 09:44:00 CET | Press release
Epsilon Carbon, a global leader in the carbon black industry, announces the launch of Terrablack, a product line that aims to shape the carbon black sector with sustainability at its core. The unveiling took place in the presence of Mr. Sajjan Jindal, Chairman and MD – JSW Group, Mr. Vikram Handa, Managing Director - Epsilon Carbon, Mr. Gaurav Mathur, CEO and Mr. Desh Deepak Misra, President - Carbon Black business at the Bharat Mobility Show’s India International Tire Exhibition, New Delhi. Terrablack is designed to address the growing demand for sustainable carbon black. Using recovered carbon black (rCB) and Tire-derived oil (TDO), this product line is formulated after 24 months of in-depth testing and collaboration to shape the future of carbon black production. It offers high-performance, eco-friendly solutions that meet the needs of both Tire and non-Tire industries. The Terrablack portfolio includes Terrablack 3310, engineered for heavy-duty applications like Tire treads, offeri
Hydrogen equipment pioneer H2SITE successfully raises EUR36 million from a consortium of investors co-led by Hy24 and SC Net Zero Ventures21.1.2025 08:42:00 CET | Press release
The Series B Funding round is co-led by Hy24 and SC Net Zero Ventures who are joined by Breakthrough Energy Ventures, Enagas Emprende, Equinor Ventures, Exergon, Ezten, and MassMutal Ventures. The investment round will support the next phases of H2SITE’s innovative hydrogen technology deployment, focusing on scaling up to multi tons per day reactors in operation by 2026. H2SITE’s solution addresses the challenges of transporting hydrogen, making the technology more accessible and creating significant cost savings. H2SITE, a deep-tech pioneer of hydrogen separation solutions, announces today the successful closing of its Series B funding round at EUR36 million from a consortium of investors, combining strategic and financial investors focused on the next growth phase. H2SITE has received support from new co-lead investors Hy24, the world’s leading low-carbon hydrogen pure-play investment manager, through its Clean Hydrogen Equipment Fund, and SC Net Zero Ventures, the climate tech ventu
Bureau Veritas to Acquire a Leading Buildings & Infrastructure Business in Italy in Line With LEAP I 2820.1.2025 19:03:00 CET | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services, announced that it has signed an agreement to acquire Contec AQS and its two owned subsidiaries Exenet and PMPI. The planned acquisition is aligned with Bureau Veritas’ LEAP | 28 strategy to expand its leadership in the Buildings and Infrastructure market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250120728164/en/ Hinda Gharbi, CEO Bureau Veritas (Photo: Business Wire) Bureau Veritas contributes to safer, sustainable, and resilient buildings and infrastructure, delivering comprehensive solutions covering the full life cycle of assets. This acquisition will expand Bureau Veritas’ Buildings and Infrastructure footprint in Italy. Contec AQS, Exenet and PMPI are established Italian brands delivering comprehensive services and technical expertise in the Buildings and Infrastructure sector. They cover construction, infrastructure and Health, Sa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom